Immatics N.V (NASDAQ: IMTX) has seen a decline in its stock price by -0.47 in relation to its previous close of 8.57. However, the company has experienced a -7.78% decline in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-08 that Two oral presentations and multiple posters on clinical and preclinical-stage candidates to be presented at SITC, demonstrating the strength of Immatics’ TCR-T PRAME franchise to target solid cancers
Is It Worth Investing in Immatics N.V (NASDAQ: IMTX) Right Now?
Moreover, the 36-month beta value for IMTX is 0.76. Analysts have varying opinions on the stock, with 6 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for IMTX is 83.43M and currently, short sellers hold a 8.02% of that float. On November 15, 2024, IMTX’s average trading volume was 525.98K shares.
IMTX’s Market Performance
IMTX’s stock has seen a -7.78% decrease for the week, with a -9.74% drop in the past month and a -25.89% fall in the past quarter. The volatility ratio for the week is 5.01%, and the volatility levels for the past 30 days are at 3.60% for Immatics N.V The simple moving average for the last 20 days is -7.54% for IMTX stock, with a simple moving average of -24.36% for the last 200 days.
Analysts’ Opinion of IMTX
Many brokerage firms have already submitted their reports for IMTX stocks, with Piper Sandler repeating the rating for IMTX by listing it as a “Overweight.” The predicted price for IMTX in the upcoming period, according to Piper Sandler is $19 based on the research report published on October 07, 2024 of the current year 2024.
Mizuho gave a rating of “Buy” to IMTX, setting the target price at $12 in the report published on March 31st of the previous year.
IMTX Trading at -18.14% from the 50-Day Moving Average
After a stumble in the market that brought IMTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.05% of loss for the given period.
Volatility was left at 3.60%, however, over the last 30 days, the volatility rate increased by 5.01%, as shares sank -10.68% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -25.37% lower at present.
During the last 5 trading sessions, IMTX fell by -7.78%, which changed the moving average for the period of 200-days by -24.91% in comparison to the 20-day moving average, which settled at $9.23. In addition, Immatics N.V saw -18.99% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for IMTX
Current profitability levels for the company are sitting at:
- -1.42 for the present operating margin
- -0.35 for the gross margin
The net margin for Immatics N.V stands at -1.04. The total capital return value is set at -0.21. Equity return is now at value -24.37, with -14.23 for asset returns.
Currently, EBITDA for the company is -88.93 million with net debt to EBITDA at 1.74. When we switch over and look at the enterprise to sales, we see a ratio of 11.61. The receivables turnover for the company is 19.66for trailing twelve months and the total asset turnover is 0.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.74.
Conclusion
To wrap up, the performance of Immatics N.V (IMTX) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
